Evotec AG Reports Start of Phase II Proof-of-Concept Quit Rate Study with EVT 302 and Results of Craving Study

HAMBURG, Germany, Sept. 11, 2008 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) announced today the start of the Phase II proof-of-concept study, investigating the effect of EVT 302 on the quit rate of patients who want to stop smoking. The Company also provided an analysis of the results of its exploratory Phase II craving study of the same compound. EVT 302 is a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B).